The Food and Drug Administration on Wednesday confirmed what many Americans had already discovered the hard way: The country is experiencing a nationwide shortage of Adderall, the drug used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.
The FDA said the shortage of “amphetamine mixed salts” — the drug behind the brand name — is driven in large part by manufacturing delays at the largest manufacturer: Israel-based Teva Pharmaceuticals.
Teva said the problems arose out of labor shortages that have been resolved. However, the shortage persists, and the end isn’t imminent: A Teva spokesperson told NBC News that patients should expect “inventory recovery in the coming months” and “intermittent delays through end of year.”
Perhaps driven by Covid lockdown-driven mental health issues and children’s difficulty in focusing in disastrous “remote schooling” arrangements imposed by public health officials and teacher unions, use of the drug has soared: Up 16% from 2019 to 2021, to reach 41.2 million prescriptions.
www.zerohedge.com/medical/fda-confirms-major-adderall-shortage-wont-end-soon